Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.12)
# 2,774
Out of 4,734 analysts
67
Total ratings
40.91%
Success rate
-3.54%
Average return
Main Sectors:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $54.54 | +21.01% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $29.55 | -25.55% | 8 | Nov 5, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $77 → $74 | $126.20 | -41.36% | 5 | Aug 8, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $3.96 | +278.79% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $22.18 | +107.39% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.15 | +61.43% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $2.89 | +73.01% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $6.86 | +89.50% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $39.05 | -28.30% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $34.63 | +50.16% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $4 | $0.34 | +1,062.79% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $1.20 | +1,816.67% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.57 | +717.12% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $4.43 | +216.03% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $12.74 | -37.21% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.53 | +2,916.59% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $54.54
Upside: +21.01%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $29.55
Upside: -25.55%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $77 → $74
Current: $126.20
Upside: -41.36%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $3.96
Upside: +278.79%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $22.18
Upside: +107.39%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.15
Upside: +61.43%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $2.89
Upside: +73.01%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $6.86
Upside: +89.50%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $39.05
Upside: -28.30%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $34.63
Upside: +50.16%
Aug 15, 2023
Maintains: Neutral
Price Target: $12 → $4
Current: $0.34
Upside: +1,062.79%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $1.20
Upside: +1,816.67%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.57
Upside: +717.12%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $4.43
Upside: +216.03%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $12.74
Upside: -37.21%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.53
Upside: +2,916.59%